将CKD群体与T1D和T2D进行比较:基于FINE-ONE和FIDELITY群体的观点
Hiddo J L Heerspink1, Rajiv Agarwal2, Antonio J Amor3
1Clinical Pharmacy and Pharmacology, University of Groningen University Medical Center Groningen, Groningen, The Netherlands.
概括
慢性病 (CKD) 影响1型和2型糖尿病患者. 专尿可能会在这些群体之间弥合治疗数据,解决1型糖尿病CKD未满足的需求.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 临床药理学 临床药理学
背景情况:
- 慢性病 (CKD) 是1型糖尿病 (T1D) 和2型糖尿病 (T2D) 的常见并发症,增加死亡率和心血管风险.
- 在T1D中治疗CKD的标准治疗方法,包括氨酸- ангиотензин系统抑制剂和血糖控制,留下疾病进展的残留风险.
- 在T1D中治疗CKD的治疗进展远远落后于T2D,这凸显了未满足的临床需求.
研究的目的:
- 为了比较T1D和T2D人群中CKD的流行病学,病理生理学和临床特征.
- 探索白色素尿作为桥梁生物标志物的实用性,用于推断T1D和T2D患有CKD的人群之间的治疗证据.
- 根据试验数据的相似性,从T2D转化为T1D,以告知finerenone有效性的潜在转化.
主要方法:
- 在T1D-CKD和T2D-CKD队列之间的流行病学,病理生理学和临床数据的比较分析.
- 评估白蛋白尿作为潜在的生物标志物,以跨越糖尿病类型的临床研究结果.
- 审查FINE-ONE试验 (T1D-CKD中的finerenone) 和与FIDELITY数据 (T2D-CKD中的finerenone) 的比较.
主要成果:
- 预计T1D和T2D群体之间CKD呈现和进展的相似之处.
- 提议将白蛋白尿作为一个关键的生物标志物,以促进证据的推断.
- 在FINE-ONE试验中,使用albuminuria变化作为主要终点,使得与T2D数据进行比较.
结论:
- 了解T1D-CKD和T2D-CKD之间的相似之处和差异对于推进治疗至关重要.
- 白蛋白尿症作为桥梁生物标志物有望加速T1D中CKD的治疗发展.
- 芬瑞在T2D-CKD中的有效性可能可转化为T1D-CKD,等待通过FINE-ONE等试验进行进一步调查.
相关概念视频
01:25Chronic Kidney Disease I: Introduction
573
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
573
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
190
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
190
01:24Chronic Kidney Disease II: Clinical Manifestations
557
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
557
01:28Chronic Kidney Disease III: Interprofessional Care
344
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
344
01:18Chronic Kidney Disease IV: Nursing Management
321
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
321
01:22Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K